• Ivana Jurin, Marko Lucijanić, Zrinka Šakić, Vanja Hulak Karlak, Armin Atić, Ana Magličić, Boris Starčević, and Irzal Hadžibegović.
• Irzal Hadžibegović, Department for Cardiovascular Diseases, University Hospital Dubrava, Avenija Gojka Šuška 6, 10000 Zagreb, Croatia, irzalh@gmail.com.
• Croat. Med. J. 2020 Oct 31; 61 (5): 440-449.

AimTo investigate the differences in the characteristics and clinical outcomes of recently diagnosed patients with atrial fibrillation (AF) receiving different types of anticoagulants in a real-life setting.MethodsWe retrospectively analyzed the charts of 1000 consecutive patients with non-valvular AF diagnosed at our institution or referred it to from 2013 to 2018.ResultsOver the observed period, the frequency of direct oral anticoagulation (DOAC) therapy use significantly increased (P = 0.002). Patients receiving warfarin had more unfavorable thromboembolic and bleeding risk factors than patients receiving DOAC. Predetermined stroke and major bleeding risks were similarly distributed among the dabigatran, rivaroxaban, and apixaban groups. Patients receiving warfarin had shorter time-to-major bleeding (TTB), time to thrombosis (TTT), and overall survival (OS) than patients receiving DOACs. After adjustment for factors unbalanced at baseline, the warfarin group showed significantly shorter OS (hazard ratio 2.27, 95% confidence interval 1.44-3.57, P<0.001], while TTB and TTT did not significantly differ between the groups. Only 37% of patients on warfarin had optimal dosing control, and they did not differ significantly in TTB, TTT, and OS from patients on DOACs.ConclusionWarfarin and DOACs are administered to different target populations, possibly due to socio-economic reasons. Patients receiving warfarin rarely obtain optimal dosing control, and experience significantly shorter survival compared with patients receiving DOACs.

36 keywords...

hide…